Department of Obstetrics and Gynecology, Wakayama Medical University School of Medicine, Wakayama, Japan.
Curr Cancer Drug Targets. 2011 May;11(4):405-11. doi: 10.2174/156800911795538057.
Recent studies have shown an activation of the local renin-angiotensin system (RAS) in various tumor tissues, including the abundant generation of angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) and the upregulation of angiotensin II type 1 receptor (AT1R) expression. Thus, considerable attention has been paid not only to the role of the RAS in cancer progression, but also to the blockade of RAS as a new approach to the treatment of human cancer. There is increasing evidence that the Ang II-AT1R pathway is involved in tumor growth, angiogenesis and metastasis in various experimental animal models, suggesting the therapeutic potential of an ACE inhibitor and AT1R blocker. In addition, specific Ang II-degrading enzymes are also expressed in tumors and play a regulatory role in tumor cell proliferation and invasion. This review focuses on the role of the RAS in the progression of gynecologic cancers, such as cervical cancer, endometrial cancer, ovarian cancer, and gestational choriocarcinoma. We present here the clinical potential of blocking the RAS as a novel and promising strategy for the treatment of gynecologic cancers.
最近的研究表明，局部肾素-血管紧张素系统 (RAS) 在各种肿瘤组织中被激活，包括血管紧张素转换酶 (ACE) 大量生成血管紧张素 II (Ang II) 和血管紧张素 II 型 1 受体 (AT1R) 表达上调。因此，人们不仅关注 RAS 在癌症进展中的作用，还关注 RAS 阻断作为治疗人类癌症的新方法。越来越多的证据表明，Ang II-AT1R 途径参与了各种实验动物模型中的肿瘤生长、血管生成和转移，提示 ACE 抑制剂和 AT1R 阻滞剂具有治疗潜力。此外，肿瘤中也表达特定的 Ang II 降解酶，并在肿瘤细胞增殖和侵袭中发挥调节作用。本综述重点讨论了 RAS 在妇科癌症（如宫颈癌、子宫内膜癌、卵巢癌和妊娠绒癌）进展中的作用。我们在此介绍了阻断 RAS 作为治疗妇科癌症的一种新颖而有前途的策略的临床潜力。
